Allicin Based Inhibition Of Eryptosis: A Novel Therapeutic Approach Against Hyperosmolarity Triggered Anemia

It is concluded from this study that hyperosmolarity is the main stimulator of eryptosis and leads to anemia in various clinical conditions, while allicin treatment helps to increase erythrocyte survival by inhibiting and attenuating various pathways and reducing eryptpotic rate. Allicin's anti-eryptotic and cytoprotective potential gives foundation for future clinical research targeting hyperosmolarity triggered anemia.